Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Kathleen M. Donahue is active.

Publication


Featured researches published by Kathleen M. Donahue.


Bioorganic & Medicinal Chemistry Letters | 1996

Inhibitors of MMP-1: an examination of P1′ Cα gem-disubstitution in the succinamide hydroxamate series

Ralph P. Robinson; John A. Ragan; Brian J. Cronin; Kathleen M. Donahue; Lori L. Lopresti-Morrow; Peter G. Mitchell; Lisa M. Reeves; Sue A. Yocum

Abstract The effect of P 1 ′ C α gem-disubstitution in a series of succinamide hydroxamate inhibitors of MMP-1 has been investigated. While in all cases P 1 ′ gem-disubstitution led to loss of potency relative to the corresponding P 1 ′ isobutyl and phenyl compounds 1 and 3 , respectively, the loss of activity was less pronounced in certain instances, e.g., the P 1 ′ gem-cyclohexyl analogue 12 IC 50 = 0.15 μM).


Bioorganic & Medicinal Chemistry Letters | 1996

Inhibitors of MMP-1: an examination of P1′ Cα gem-disubstitution in the N-carboxyalkylamine and glutaramide carboxylate series

Ralph P. Robinson; Brian J. Cronin; Kathleen M. Donahue; Brian P. Jones; Lori L. Lopresti-Morrow; Peter G. Mitchell; James P. Rizzi; Lisa M. Reeves; Sue A. Yocum

Abstract Modification of the N-carboxyalkylamine 3 by independent replacement of the P1′ NH group for CH2 and introduction of P1′ gem-cyclohexyl substitution affords compounds 5 and 6a which retain appreciable activity against MMP-1 (IC50s = 0.023 μM and 0.09 μM, respectively). The glutaramide 7a which incorporates both these structural changes also retains potent activity (IC50 = 0.038 μM).


Tetrahedron Letters | 1989

A novel rearrangement forming 4,5,6,11-tetra-hydrobenzo[6,7]cycloocta[1,2-b]thiophen-6,11-imines

Ralph P. Robinson; Kathleen M. Donahue; Nicholas Alex Saccomano

Exposure of the spirocyclic isoindolines 9 and 16 and the spirocyclic ether 23 to HBr gas in methylene chloride at 0°C leads to the formation of the bridged heterocycles 10, 17, and 24 respectively. These novel rearrangements probably occur via retro-Mannich fragmentation and subsequent intramolecular Mannich reaction on the thiophene ring.


Journal of Medicinal Chemistry | 1996

Discovery of the Hemifumarate and (α-l-Alanyloxy)methyl Ether as Prodrugs of an Antirheumatic Oxindole: Prodrugs for the Enolic OH Group

Ralph P. Robinson; Lawrence A. Reiter; Wayne E. Barth; Anthony Michael Campeta; Kelvin Cooper; Brian J. Cronin; Rosalina Destito; Kathleen M. Donahue; Fred C. Falkner; Eugene F. Fiese; Diane L. Johnson; Alexander V. Kuperman; Theodore E. Liston; Deborah Malloy; John J. Martin; David Young Mitchell; Frank W. Rusek; Sheri L. Shamblin; Charles F. Wright


Journal of Medicinal Chemistry | 2005

Theoretical and Experimental Design of Atypical Kinase Inhibitors: Application to p38 MAP Kinase.

Kim F. McClure; Yuriy A. Abramov; Ellen R. Laird; John T. Barberia; Weiling Cai; Thomas J. Carty; Santo R. Cortina; Dennis E. Danley; Alan J. Dipesa; Kathleen M. Donahue; Mark A. Dombroski; Nancy C. Elliott; Christopher A. Gabel; Seungil Han; Thomas R. Hynes; Peter K. LeMotte; Mahmoud N. Mansour; Eric S. Marr; Michael A. Letavic; Jayvardhan Pandit; David H. Brown Ripin; Francis J. Sweeney; Douglas H. Tan; Yong Tao


Journal of Organic Chemistry | 1992

Synthesis of a peptidyl difluoro ketone bearing the aspartic acid side chain: an inhibitor of interleukin-1.beta. converting enzyme

Ralph P. Robinson; Kathleen M. Donahue


Bioorganic & Medicinal Chemistry Letters | 2004

Pyran-containing sulfonamide hydroxamic acids: potent MMP inhibitors that spare MMP-1.

Lawrence A. Reiter; Ralph P. Robinson; Kim F. McClure; Christopher S. Jones; Matthew R. Reese; Peter G. Mitchell; Ivan G. Otterness; Marcia L. Bliven; Jennifer Liras; Santo R. Cortina; Kathleen M. Donahue; James D. Eskra; Richard J. Griffiths; Mary E. Lame; Arturo Lopez-Anaya; Gary J. Martinelli; Shunda M. McGahee; Sue A. Yocum; Lori L. Lopresti-Morrow; Lisa M. Tobiassen; Marcie L. Vaughn-Bowser


Journal of Medicinal Chemistry | 2000

Structure-Based Design and Synthesis of a Potent Matrix Metalloproteinase-13 Inhibitor Based on a Pyrrolidinone Scaffold

Ralph P. Robinson; Ellen R. Laird; James F. Blake; Jon Bordner; Kathleen M. Donahue; Lori L. Lopresti-Morrow; Peter G. Mitchell; Matthew R. Reese; Lisa M. Reeves; Ethan J. Stam; Sue A. Yocum


Bioorganic & Medicinal Chemistry Letters | 2006

Structure-activity relationships of triazolopyridine oxazole p38 inhibitors: identification of candidates for clinical development.

Kim F. McClure; Michael A. Letavic; Amit S. Kalgutkar; Christopher A. Gabel; Laurent P. Audoly; John T. Barberia; John Frederick Braganza; Demetrius Carter; Thomas J. Carty; Santo R. Cortina; Mark A. Dombroski; Kathleen M. Donahue; Nancy C. Elliott; Colleen P. Gibbons; Crystal K. Jordan; Alexander V. Kuperman; Jeff M. Labasi; Ronald E. Laliberte; Jennifer M. McCoy; Brian M. Naiman; Kendra Louise Nelson; Hang T. Nguyen; Kevin M. Peese; Francis J. Sweeney; Timothy J. Taylor; Catherine E. Trebino; Yuriy A. Abramov; Ellen R. Laird; Walter Volberg; Jun Zhou


Bioorganic & Medicinal Chemistry Letters | 2001

Design and synthesis of 2-oxo-imidazolidine-4-carboxylic acid hydroxyamides as potent matrix metalloproteinase-13 inhibitors

Ralph P. Robinson; Ellen R. Laird; Kathleen M. Donahue; Lori L. Lopresti-Morrow; Peter G. Mitchell; Matthew R. Reese; Lisa M. Reeves; Amber I. Rouch; Ethan J. Stam; Sue A. Yocum

Collaboration


Dive into the Kathleen M. Donahue's collaboration.

Researchain Logo
Decentralizing Knowledge